ערך בספרים למניה: Scinai Immunotherapeutics Ltd. (SCNI)

Equity per share reflects the trajectory of Scinai Immunotherapeutics (SCNI) as it undergoes intensive R&D to create innovative nanobodies. The value 10.75 is recorded as the baseline value. Revenue is projected to be generated through the implementation of treatments against influenza, COVID-19, and dermatitis. However, fierce competition for government grants and pressure from vaccination behemoths create significant risks for scaling the business.

Amidst a fierce scientific race in biopharmaceuticals, Scinai Immunotherapeutics (SCNI) relies on efficient capital management to compete with global leaders. The dynamics of the net book value per share reflect the remaining assets after all liabilities are settled, demonstrating the business's real financial resilience. Growth in this indicator confirms a strengthening fundamental base, whereas stagnation may signal an inefficient use of resources.